A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

Abali, HuseyinYalcin, SuayibOnal, Huseyin CemDane, FaysalOksuzoglu, BernaOzdemir, NuriyeMertsoylu, HuseyinArtac, MehmetCamci, CelalettinKarabulut, BulentBasal, Fatma BugdayciBudakoglu, BurcinSendur, Mehmet Ali NahitGoktas, BurceOzdener, FatihCalisgan, Arzu2019-10-272019-10-2720160732-183X1527-7755https://doi.org/10.1200/jco.2016.34.4_suppl.tps182https://hdl.handle.net/11454/53070Gastrointestinal Cancers Symposium -- JAN 21-23, 2016 -- San Francisco, CAen10.1200/jco.2016.34.4_suppl.tps182info:eu-repo/semantics/closedAccessA study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).Conference Object344WOS:000378109600176Q1